Specialised Therapeutics NIKTIMVO Approved for cGVHD
Singapore | May 4, 2026 Specialised Therapeutics has announced that NIKTIMVO® (axatilimab) has received regulatory approval from the Therapeutic...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Singapore | May 4, 2026 Specialised Therapeutics has announced that NIKTIMVO® (axatilimab) has received regulatory approval from the Therapeutic...
Toronto, Canada | May 1, 2026 Apotex has received Health Canada approval for Apo-Semaglutide Injection™, a generic equivalent of...
FOSTER CITY, Calif., April 17, 2026 Gilead Sciences, Inc. has announced that it has obtained all required regulatory approvals...
Madison, New Jersey, U.S. | April 15, 2026 LEO Pharma has announced that the U.S. Food and Drug Administration...
Rockville, Maryland, U.S. | April 15, 2026 Leadiant Biosciences has announced a major regulatory milestone with Health Canada approval...
WALTHAM, Massachusetts | April 9, 2026 Swedish Orphan Biovitrum (Sobi) has announced that Health Canada has approved EMPAVELI® (pegcetacoplan),...
MIRAMAR, Fla., April 9, 2026 DifGen Pharmaceuticals LLC, in collaboration with Apotex Inc., has announced that the U.S. Food...
SALT LAKE CITY, April 2, 2026 Co-Diagnostics, Inc. announced that its joint venture CoMira Diagnostics has received approval to...
LANGHORNE, Pa., March 30, 2026 Savara Inc. has achieved a major regulatory milestone as the European Medicines Agency (EMA)...
BOSTON, March 19, 2026 Rhythm Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Imcivree (setmelanotide) for...
